Enhanced antitumor effects by combination gene therapy using MDR1 gene shRNA and HSV1-tk in a xenograft mouse model

Cancer Letters

Volumn 291, Issue 1, 2010, Pages 83-89

  Lee, Sang Woo ^a   Lee, You La ^a   Lee, Yong Jin ^a   Park, Seung Yoon ^b   Kim, In San ^c   Choi, Tae Hyun ^d   Ha, Jeoung Hee ^a   Ahn, Byeong Cheol ^a   Lee, Jaetae ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Dongguk University College of Medicine   (South Korea)

^c Kyungpook National University   (South Korea)

^d Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

131I FIAU imaging; Combination gene therapy; HSV1 tk; MDR1; shRNA

Indexed keywords

5 IODO 2' FLUORO 2' DEOXY 1 BETA DEXTRO ARABINOFURANOSYLURACIL I 131; DOXORUBICIN; GANCICLOVIR; MULTIDRUG RESISTANCE PROTEIN 1; PENCICLOVIR; PROTEIN TYROSINE KINASE; RADIOACTIVE IODINE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ARABINOFURANOSYLURACIL; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOXORUBICIN; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MICE; MICE, INBRED BALB C; P-GLYCOPROTEIN; RNA, SMALL INTERFERING; THYMIDINE KINASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77949875281     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.10.002     Document Type: Article

References (36)

1. Moolten F.L., and Wells J.M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82 (1990) 297-300
2. Ilsley D.D., Lee S.H., Miller W.H., and Kuchta R.D. Acyclic guanosine analogs inhibit DNA polymerases, alpha, delta and epsilon with very different potencies and have unique mechanisms of action. Biochemistry 34 (1995) 2504-2510
3. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L., and Abraham G.N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53 (1993) 5274-5283
4. Dilber M.S., Abedi M.R., Christensson B., Björkstrand B., Kidder G.M., Naus C.C., Gahrton G., and Smith C.I. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 57 (1997) 1523-1528
5. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliver. Rev. 55 (2003) 3-29
6. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Craig C.M. Potent and specific genetic interference by double stranded RNA in caenorhabditis elegans. Nature 391 (1998) 806-811
7. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
8. Nykanen A., Haley B., and Zamore P.D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107 (2001) 309-321
9. Gambhir S.S., Bauer E., Black M.E., Liang Q., Kokoris M.S., Barrio J.R., Iyer M., Namavari M., Phelps M.E., and Herschman H.R. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc. Natl. Acad. Sci. USA 97 (2000) 2785-2790
10. Tjuvajev J.G., Doubrovin M., Akhurst T., Cai S., Balatoni J., Alauddin M.M., Finn R., Bornmann W., Thaler H., Conti P.S., and Blasberg R.G. Comparison of radiolabeled nucleoside probes (FIAU, FHBG and FHPG) for PET imaging of HSV1-tk gene expression. J. Nucl. Med. 43 (2002) 1072-1083
11. Min J.J. Translational imaging with PET reporter gene approaches. Nucl. Med. Mol. Imag. 40 (2006) 279-292
12. Park S.Y., Lee W., Lee J., and Kim I.S. Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett. 261 (2008) 205-214
13. Willhauck M.J., Sharif Samani B.R., Klutz K., Cengic N., Wolf I., Mohr L., Geissler M., Senekowitsch-Schmidtke R., Göke B., Morris J.C., and Spitzweg C. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther. 15 (2008) 214-223
14. Deng W.P., Yang W.K., Lai W.F., Liu R.S., Hwang J.J., Yang D.M., Fu Y.K., and Wang H.E. Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir. Eur. J. Nucl. Med. Mol. Imag. 31 (2004) 99-109
15. Altaner C. Prodrug cancer gene therapy. Cancer Lett. 270 (2008) 191-201
16. Sterman D.H., Treat J., Litzky L.A., Amin K.M., Coonrod L., Molnar-Kimber K., Recio A., Knox L., Wilson J.M., Albelda S.M., and Kaiser L.R. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9 (1998) 1083-1092
17. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11 (2000) 2389-2401
18. Immonen A., Vapalahti M., Tyynelä K., Hurskainen H., Sandmair A., Vanninen R., Langford G., Murray N., and Ylä-Herttuala S. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised,806 controlled study. Mol. Ther. 10 (2004) 967-972
19. Sterman D.H., Recio A., Vachani A., Sun J., Cheung L., DeLong P., Amin K.M., Litzky L.A., Wilson J.M., Kaiser L.R., and Albelda S.M. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin. Cancer Res. 11 (2005) 7444-7453
20. Black M.E., Kokoris M.S., and Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 61 (2001) 3022-3026
21. Boucher P.D., Ostruszka L.J., Murphy P.J., and Shewach D.S. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 9 (2002) 1023-1030
22. Boucher P.D., and Shewach D.S. In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine. Mol. Ther. 12 (2005) 1064-1071
23. Hayashi K., Lee J.B., Maitani Y., Toyooka N., Nemoto H., and Hayashi T. The role of a HSV thymidine kinase stimulating substance, scopadulciol in improving the efficacy of cancer gene therapy. J. Gene Med. 8 (2006) 1056-1067
24. Stefani A.L., Barzon L., Castagliuolo I., Guido M., Pacenti M., Parolin C., Farinati F., and Palù G. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J. Hepatol. 42 (2005) 728-735
25. Kagaya T., Nakamoto Y., Sakai Y., Tsuchiyama T., Yagita H., Mukaida N., and Kaneko S. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther. 13 (2006) 357-366
26. Moretti J.L., Hauet N., Caglar M., Rebillard O., and Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur. J. Nucl. Med. Mol. Imag. 32 (2005) 836-842
27. Tan B., Piwnica-Worms D., and Ratner L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12 (2000) 450-458
28. Wu H., Hait W., and Yang J.M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 63 (2003) 1515-1519
29. Stierle V., Laigle A., and Jolle B. Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs. Biochem. Pharmacol. 70 (2005) 1424-1430
30. Matsui Y., Kobayashi N., Nishikawa M., and Takakura Y. Sequence-specific suppression of MDR1a/1b expression in mice via RNA interference. Pharm. Res. 22 (2005) 2091-2098
31. MacDiarmid J.A., Amaro-Mugridge N.B., Madrid-Weiss J., Sedliarou I., Wetzel S., Kochar K., Brahmbhatt V.N., Phillips L., Pattison S.T., Petti C., Stillman B., Graham R.M., and Brahmbhatt H. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 27 (2009) 643-651
32. Gambhir S.S., Herschman H.R., Cherry S.R., Barrio J.R., Satyamurthy N., Toyokuni T., Phelps M.E., Larson S.M., Balatoni J., Finn R., Sadelain M., Tjuvajev J., and Blasberg R. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2 (2000) 118-138
33. Jacobs A., Voges J., Reszka R., Lercher M., Gossmann A., Kracht L., Kaestle C., Wagner R., Wienhard K., and Heiss W.D. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358 (2001) 727-729
34. Peñuelas I., Mazzolini G., Boán J.F., Sangro B., Martí-Climent J., Ruiz M., Ruiz J., Satyamurthy N., Qian C., Barrio J.R., Phelps M.E., Richter J.A., Gambhir S.S., and Prieto J. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128 (2005) 1787-1795
35. 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer. J. Nucl. Med. 47 (2006) 1161-1171
36. Deng W.P., Wu C.C., Lee C.C., Yang W.K., Wang H.E., Liu R.S., Wei H.J., Gelovani J.G., Hwang J.J., Yang D.M., Fu Y.K., and Wu C.W. Serial in vivo imaging of the lung metastases model and gene therapy using HSV1-tk and ganciclovir. J. Nucl. Med. 47 (2006) 877-884